Boston Scientific Q2 2024 Adj EPS $0.62 Beats $0.58 Estimate, Sales $4.120B Beat $4.017B Estimate
Portfolio Pulse from Benzinga Newsdesk
Boston Scientific reported Q2 2024 adjusted EPS of $0.62, beating the estimate of $0.58. Sales were $4.120 billion, surpassing the expected $4.017 billion.
July 24, 2024 | 10:32 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Boston Scientific's Q2 2024 earnings and sales both exceeded analyst estimates, indicating strong financial performance.
The company's adjusted EPS of $0.62 beat the estimate of $0.58, and sales of $4.120 billion surpassed the expected $4.017 billion. This positive financial performance is likely to boost investor confidence and drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100